Harsanyi Zsolt 4

4 · Emergent BioSolutions Inc. · Filed May 4, 2026

AI-generated summary of this filing

Updated May 4, 2026

Emergent BioSolutions (EBS) Chairman Harsanyi Receives RSUs & Options

What Happened

Zsolt Harsanyi, Chairman and director of Emergent BioSolutions (EBS), received equity awards on April 30, 2026: 25,344 restricted stock units (RSUs) and 11,296 derivative securities (stock options). Both awards were granted as part of routine board and committee compensation and show $0 cash paid at grant (standard for awards).
The RSUs (25,344) represent rights to receive one share per RSU upon vesting. The 11,296 derivative items are stock options (each option entitles the holder to buy one share upon vesting at the option exercise price). The filing records the acquisition price as $0.00 for the grants (grant value not shown in the excerpt).

Key Details

Transaction date: 2026-04-30; Form 4 filed 2026-05-04 (timely under the two-business-day rule).
Price: $0.00 listed for the award grants (standard for RSU/option grants); exercise price for the options is not specified in the provided excerpt.
Vesting: Both the RSUs and options vest on the day prior to the one-year anniversary of the grant (the “Annual Grant Vesting Date”), contingent on Harsanyi remaining a board member through that date (see footnotes F1–F2).
How option grant size was set: Number of options was calculated by converting 25% of director compensation into option counts using a Black‑Scholes per‑option value (per footnote F3).
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing timeliness: Filed on May 4, 2026 for a 4/30/2026 grant — appears timely.

Context

These are routine, annual equity awards for non-employee directors used to compensate board service. RSUs pay out shares at vesting; options give the right to buy shares at a set exercise price once vested.
Such awards are common and reflect compensation, not an open‑market purchase or sale; they do not by themselves indicate the insider’s view of the company’s near‑term stock prospects.

Form 4

Period: 2026-04-30

DirectorChairman

Transactions

Award
Common Stock
[F1]
2026-04-30+25,344→ 149,076 total
Award
Stock Option (Right to Buy)
[F2][F3]
2026-04-30+11,296→ 11,296 total
Exercise: $7.99Exp: 2033-04-30→ Common Stock (11,296 underlying)

Footnotes (3)

[F1]Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
[F2]Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
[F3]The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Signature

/s/ Richard S. Lindahl, Attorney-in-fact|2026-05-04

1 file